Jommel Macaraeg
Overview
Explore the profile of Jommel Macaraeg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yashar W, Curtiss B, Coleman D, VanCampen J, Kong G, Macaraeg J, et al.
Mol Cancer Res
. 2023 Mar;
21(7):631-647.
PMID: 36976323
Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.
2.
Braun T, Estabrook J, Schonrock Z, Curtiss B, Darmusey L, Macaraeg J, et al.
Leukemia
. 2022 Dec;
37(2):478-487.
PMID: 36526735
Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis....
3.
Macaraeg J, Reinhard I, Ward M, Carmeci D, Stanaway M, Moore A, et al.
Biol Open
. 2022 Jun;
11(7).
PMID: 35678140
Haspin is a histone kinase that promotes error-free chromosome segregation by recruiting the chromosomal passenger complex (CPC) to mitotic and meiotic chromosomes. Haspin remains less well studied than other M-phase...
4.
Curtiss B, VanCampen J, Macaraeg J, Kong G, Taherinasab A, Tsuchiya M, et al.
Leukemia
. 2022 May;
36(7):1781-1793.
PMID: 35590033
Responses to kinase-inhibitor therapy in AML are frequently short-lived due to the rapid development of resistance, limiting the clinical efficacy. Combination therapy may improve initial therapeutic responses by targeting pathways...